Engineered Nanomaterials: The Challenges and Opportunities for Nanomedicines

被引:69
作者
Albalawi, Fahad [1 ,2 ,3 ]
Hussein, Mohd Zobir [3 ]
Fakurazi, Sharida [4 ,5 ]
Masarudin, Mas Jaffri [6 ]
机构
[1] King Fahad Specialist Hosp Tabuk, Dept Med Lab, Tabuk, Saudi Arabia
[2] King Fahad Specialist Hosp Tabuk, Blood Bank, Tabuk, Saudi Arabia
[3] Univ Putra Malaysia, Inst Adv Technol ITMA, Mat Synth & Characterizat Lab, Serdang, Selangor, Malaysia
[4] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Human Anat, Serdang, Selangor, Malaysia
[5] Inst Biosci, Nat Med & Prod Res Lab, Serdang, Selangor, Malaysia
[6] Univ Putra Malaysia, Fac Biotechnol & Biomol Sci, Dept Cell & Mol Biol, Serdang, Selangor, Malaysia
关键词
engineered nanomaterials; nanomedicine; nanotoxicology; particle tracking analysis; asymmetric flow field-flow fractionation; Taylor dispersion analysis; TAYLOR DISPERSION ANALYSIS; IN-VITRO TOXICITY; NANOPARTICLE TRACKING ANALYSIS; DRUG-DELIVERY; INORGANIC NANOPARTICLES; PHYSICOCHEMICAL PROPERTIES; MAGNETIC NANOPARTICLES; GOLD NANOPARTICLES; CELLULAR TOXICITY; SAFETY ASSESSMENT;
D O I
10.2147/IJN.S288236
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
The emergence of nanotechnology as a key enabling technology over the past years has opened avenues for new and innovative applications in nanomedicine. From the business aspect, the nanomedicine market was estimated to worth USD 293.1 billion by 2022 with a perception of market growth to USD 350.8 billion in 2025. Despite these opportunities, the underlying challenges for the future of engineered nanomaterials (ENMs) in nanomedicine research became a significant obstacle in bringing ENMs into clinical stages. These challenges include the capability to design bias-free methods in evaluating ENMs' toxicity due to the lack of suitable detection and inconsistent characterization techniques. Therefore, in this literature review, the state-of-the-art of engineered nanomaterials in nanomedicine, their toxicology issues, the working framework in developing a toxicology benchmark and technical characterization techniques in determining the toxicity of ENMs from the reported literature are explored.
引用
收藏
页码:161 / 184
页数:24
相关论文
共 190 条
[1]   Overview of novel strategies for the delivery of anthracyclines to cancer cells by liposomal and polymeric nanoformulations [J].
Alavi, Mehran ;
Varma, Rajender S. .
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2020, 164 :2197-2203
[2]   Nano liposomal and cubosomal formulations with platinum-based anticancer agents: therapeutic advances and challenges [J].
Alavi, Mehran ;
Webster, Thomas J. .
NANOMEDICINE, 2020, 15 (24) :2399-2410
[3]   Functionalized carbon-based nanomaterials and quantum dots with antibacterial activity: a review [J].
Alavi, Mehran ;
Jabari, Erfan ;
Jabbari, Esmaiel .
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2021, 19 (01) :35-44
[4]   Recent progress in nanoformulations of silver nanoparticles with cellulose, chitosan, and alginic acid biopolymers for antibacterial applications [J].
Alavi, Mehran ;
Rai, Mahendra .
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2019, 103 (21-22) :8669-8676
[5]   Ultrasound assisted-phytofabricated Fe3O4 NPs with antioxidant properties and antibacterial effects on growth, biofilm formation, and spreading ability of multidrug resistant bacteria [J].
Alavi, Mehran ;
Karimi, Naser .
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2019, 47 (01) :2405-2423
[6]   Liposomal drug delivery systems: From concept to clinical applications [J].
Allen, Theresa M. ;
Cullis, Pieter R. .
ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (01) :36-48
[7]  
Analysis M., 2020, BIOMATERIALS MED APP, V3, P2019
[8]  
[Anonymous], 2018, ISSUES IN TOXICOLOGY, DOI DOI 10.1016/J.NBD.2018.07.002
[9]   Nanoparticles in the clinic: An update [J].
Anselmo, Aaron C. ;
Mitragotri, Samir .
BIOENGINEERING & TRANSLATIONAL MEDICINE, 2019, 4 (03)
[10]   Magnetic Nanoparticles Cross the Blood-Brain Barrier: When Physics Rises to a Challenge [J].
Antonia Busquets, Maria ;
Espargaro, Alba ;
Sabate, Raimon ;
Estelrich, Joan .
NANOMATERIALS, 2015, 5 (04) :2231-2248